Oxidative stress from reflux esophagitis to esophageal cancer: the alleviation with antioxidants

Free Radical Research

Volumn 50, Issue 10, 2016, Pages 1071-1079

  Song, Ji Hyun ^a   Han, Young Min ^b   Kim, Won Hee ^a   Park, Jong Min ^b   Jeong, Migyeong ^b   Go, Eun Jin ^b   Hong, Sung Pyo ^a   Hahm, Ki Baik ^a,b  

^a CHA University   (South Korea)

^b Cancer Prevention Research Center   (South Korea)

Author keywords

Antioxidant; Barrett associated adenocarcinoma; Barrett s esophagus; chemoprevention; esophageal adenocarcinoma; oxidative stress; reflux esophagitis

Indexed keywords

ACID; ANTIOXIDANT; BILE ACID; ECABET; PANTOPRAZOLE; REBAMIPIDE;

BARRETT ESOPHAGUS; CHEMOPROPHYLAXIS; CROSS LINKING; DRUG DELIVERY SYSTEM; DRUG MECHANISM; ESOPHAGEAL ADENOCARCINOMA; HEALING; HUMAN; MALIGNANT TRANSFORMATION; MOLECULAR PATHOLOGY; NONHUMAN; OXIDATIVE STRESS; REFLUX ESOPHAGITIS; REVIEW; ANIMAL; C57BL MOUSE; ESOPHAGITIS; ESOPHAGUS TUMOR; GENETICS; MOUSE;

ANIMALS; ANTIOXIDANTS; ESOPHAGEAL NEOPLASMS; ESOPHAGITIS; HUMANS; MICE; MICE, INBRED C57BL; OXIDATIVE STRESS;

EID: 84994607188     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.1080/10715762.2016.1181262     Document Type: Review

References (40)

1. T.Y.Oh, J.S.Lee, B.O.Ahn, H.Cho, W.B.Kim, Y.B.Kim,. Oxidative stress is more important than acid in the pathogenesis of reflux oesophagitis in rats. Gut 2001;49:364–371.
2. T.Y.Oh, J.S.Lee, B.O.Ahn, H.Cho, W.B.Kim, Y.B.Kim,. Oxidative damages are critical in pathogenesis of reflux esophagitis:implication of antioxidants in its treatment. Free Radic Biol Med 2001;30:905–915.
3. M.Inayama, N.Hashimoto, T.Tokoro, H.Shiozaki Involvement of oxidative stress in experimentally induced reflux esophagitis and esophageal cancer. Hepatogastroenterology 2007;54:761–765.
4. Y.Li, R.C.Martin, 2nd. Reflux injury of esophageal mucosa:experimental studies in animal models of esophagitis, Barrett’s esophagus and esophageal adenocarcinoma. Dis Esophagus 2007;20:372–378.
5. Z.Arora, A.Garber, P.N.Thota Risk factors for Barrett’s esophagus. J Dig Dis 2016. [Epub ahead of print]. doi:10.1111/1751-2980.12332.
6. R.F.Souza, K.Krishnan, S.J.Spechler Acid, bile, and CDX:the ABCs of making Barrett’s metaplasia. Am J Physiol Gastrointest Liver Physiol 2008;295:G211–G218.
7. B.J.Colleypriest, J.M.Farrant, J.M.Slack, D.Tosh The role of Cdx2 in Barrett’s metaplasia. Biochem Soc Trans 2010;38:364–369.
8. B.J.Colleypriest, S.G.Ward, D.Tosh How does inflammation cause Barrett’s metaplasia? Curr Opin Pharmacol 2009;9:721–726.
9. Y.Tamagawa, N.Ishimura, G.Uno, T.Yuki, H.Kazumori, S.Ishihara,. Notch signaling pathway and Cdx2 expression in the development of Barrett’s esophagus. Lab Invest 2012;92:896–909.
10. J.M.Slack, B.J.Colleypriest, J.M.Quinlan, W.Y.Yu, M.J.Farrant, D.Tosh Barrett’s metaplasia:molecular mechanisms and nutritional influences. Biochem Soc Trans 2010;38:313–319.
11. A.Baruah, N.Buttar, R.Chandra, X.Chen, N.J.Clemons, D.Compare,. Translational research on Barrett’s esophagus. Ann N Y Acad Sci 2014;1325:170–186.
12. S.Morita, Y.Matsumoto, S.Okuyama, K.Ono, Y.Kitamura, A.Tomori,. Bile acid-induced expression of activation-induced cytidine deaminase during the development of Barrett’s oesophageal adenocarcinoma. Carcinogenesis 2011;32:1706–1712.
13. N.C.Guy, H.Garewal, H.Holubec, H.Bernstein, C.M.Payne, C.Bernstein,. A novel dietary-related model of esophagitis and Barrett’s esophagus, a premalignant lesion. Nutr Cancer 2007;59:217–227.
14. J.R.Olliver, L.J.Hardie, Y.Gong, S.Dexter, D.Chalmers, K.M.Harris, C.P.Wild Risk factors, DNA damage, and disease progression in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev 2005;14:620–625.
15. P.A.Atherfold, J.A.Jankowski Molecular biology of Barrett’s cancer. Best Pract Res Clin Gastroenterol 2006;20:813–827.
16. M.Pera, M.J.Brito, R.Poulsom, E.Riera, L.Grande, A.Hanby, N.A.Wright Duodenal-content reflux esophagitis induces the development of glandular metaplasia and adenosquamous carcinoma in rats. Carcinogenesis 2000;21:1587–1591.
17. D.H.Wang, N.J.Clemons, T.Miyashita, A.J.Dupuy, W.Zhang, A.Szczepny,. Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett’s metaplasia. Gastroenterology 2010;138:1810–1822.
18. K.Dvorak, C.M.Payne, M.Chavarria, L.Ramsey, B.Dvorakova, H.Bernstein,. Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage:relevance to the pathogenesis of Barrett’s oesophagus. Gut 2007;56:763–771.
19. M.A.Jabri, H.Tounsi, K.Rtibi, L.Marzouki, M.Sakly, H.Sebai Ameliorative and antioxidant effects of myrtle berry seed (Myrtus communis) extract during reflux-induced esophagitis in rats. Pharm Biol 2016. [Epub ahead of print]. doi:10.3109/13880209.2015.1107748.
20. O.J.Kwon, B.K.Choo, J.Y.Lee, M.Y.Kim, S.H.Shin, B.I.Seo,. Protective effect of Rhei Rhizoma on reflux esophagitis in rats via Nrf2-mediated inhibition of NF-κB signaling pathway. BMC Complement Altern Med 2016;16:7.
21. A.K.Giri, J.K.Rawat, M.Singh, S.Gautam, G.Kaithwas Effect of lycopene against gastroesophageal reflux disease in experimental animals. BMC Complement Altern Med 2015;15:110.
22. J.W.Kang, S.M.Lee Protective effects of chlorogenic acid against experimental reflux esophagitis in rats. Biomol Ther (Seoul) 2014;22:420–425.
23. Z.Zamora, V.Molina, R.Mas, Y.Ravelo, Y.Perez, A.Oyarzabal Protective effects of D-002 on experimentally induced gastroesophageal reflux in rats. World J Gastroenterol 2014;20:2085–2090.
24. I.Brzozowska, M.Strzalka, D.Drozdowicz, S.J.Konturek, T.Brzozowski Mechanisms of esophageal protection, gastroprotection and ulcer healing by melatonin. implications for the therapeutic use of melatonin in gastroesophageal reflux disease (GERD) and peptic ulcer disease. Curr Pharm Des 2014;20:4807–4815.
25. H.D.Appelman, M.Matejcic, M.I.Parker, R.H.Riddell, M.Salemme, P.E.Swanson, V.Villanacci Progression of esophageal dysplasia to cancer. Ann N Y Acad Sci 2014;1325:96–107.
26. L.A.Feagins, R.F.Souza Molecular targets for treatment of Barrett’s esophagus. Dis Esophagus 2005;18:75–86.
27. S.L.Picardo, S.G.Maher, J.N.O’Sullivan, J.V.Reynolds Barrett’s to oesophageal cancer sequence:a model of inflammatory-driven upper gastrointestinal cancer. Dig Surg 2012;29:251–260.
28. J.S.Lee, T.Y.Oh, B.O.Ahn, H.Cho, W.B.Kim, Y.B.Kim,. Involvement of oxidative stress in experimentally induced reflux esophagitis and Barrett’s esophagus:clue for the chemoprevention of esophageal carcinoma by antioxidants. Mutat Res 2001;480–481:189–200.
29. M.H.Zeb, A.Baruah, S.K.Kossak, N.S.Buttar Chemoprevention in Barrett’s esophagus:current status. Gastroenterol Clin North Am 2015;44:391–413.
30. K.B.Dunbar, R.F.Souza, S.J.Spechler The effect of proton pump inhibitors on Barrett’s esophagus. Gastroenterol Clin North Am 2015;44:415–424.
31. T.Miyashita, F.A.Shah, J.W.Harmon, G.P.Marti, D.Matsui, K.Okamoto,. Do proton pump inhibitors protect against cancer progression in GERD? Surg Today 2013;43:831–837.
32. C.E.Woodall, Y.Li, Q.H.Liu, J.Wo, R.C.Martin Chemoprevention of metaplasia initiation and carcinogenic progression to esophageal adenocarcinoma by resveratrol supplementation. Anticancer Drugs 2009;20:437–443.
33. R.C.Martin, Q.Liu, J.M.Wo, M.B.Ray, Y.Li Chemoprevention of carcinogenic progression to esophageal adenocarcinoma by the manganese superoxide dismutase supplementation. Clin Cancer Res 2007;13:5176–5182.
34. J.Akiyama, S.Komanduri, V.J.Konda, H.Mashimo, S.Noria, G.Triadafilopoulos Endoscopy for diagnosis and treatment in esophageal cancers:high-technology assessment. Ann N Y Acad Sci 2014;1325:77–88.
35. T.Nguyen, Z.Duan, A.D.Naik, J.R.Kramer, H.B.El-Serag Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett’s esophagus:a nested case-control study. Gastroenterology 2015;149:1392–1398.
36. D.M.Nguyen, P.Richardson, H.B.El-Serag Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus. Gastroenterology 2010;138:2260–2266.
37. I.L.Beales, I.Vardi, L.Dearman Regular statin and aspirin use in patients with Barrett’s oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma. Eur J Gastroenterol Hepatol 2012;24:917–923.
38. G.M.Masclee, P.M.Coloma, M.C.Spaander, E.J.Kuipers, M.C.Sturkenboom NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett’s oesophagus:a population-based case-control study. BMJ Open 2015;5:e006640.
39. B.J.Reid, X.Li, P.C.Galipeau, T.L.Vaughan Barrett’s oesophagus and oesophageal adenocarcinoma:time for a new synthesis. Nat Rev Cancer 2010;10:87–101.
40. A.Baruah, N.S.Buttar Chemoprevention in Barrett’s oesophagus. Best Pract Res Clin Gastroenterol 2015;29:151–165.